Pfizer Inc.

NYSE:PFE   3:59:59 PM EDT
40.12
+0.10 (+0.25%)
4:07:28 PM EDT: $40.12 0.00 (0.00%)
Products

BioNTech And Pfizer: Additional Data From Phase 1/2 Trial With Bnt162b2

Published: 12/14/2020 11:09 GMT
Pfizer Inc. (PFE) - Pfizer and Biontech Provide Data From German Phase 1/2 Study Further Characterizing Immune Response Following Immunization With Lead Covid-19 Vaccine Candidate Bnt162b2.
Study Results Demonstrate That Bnt162b2 Elicits a Combined Adaptive Humoral and Cellular Immune Response Against Sars-cov-2 and Provide Insights Into Composite Nature of Bnt162b2-induced T Cell Immunity.
Data Confirm Previous Findings From U.S. Trial Demonstrating a Good Safety Profile and Robust Induction of Antibody Responses With a Longer Follow-up Period of 85 Days.